Podcast appearances and mentions of Richard Scott

Welcome to the CavasShips Podcast with Christopher P. Cavas and Chris Servello…a weekly podcast looking at naval and maritime events and issues of the day – in the US, across the seas and around the world. This week…the view from Europe. Lots going on outside the USA. Veteran naval journalists Richard Scott and Xavier Vavasseur are back to bring us up to date on French and British carrier deployments, trends in Europe, and some of the latest naval news from Asia. 

Send us a textStill life? Not as we know it. Trembling with tension and beauty, and roses that cup darkness and secret trauma... Hear Richard Scott share from his extraordinary new collection That Broke into Shining Crystals, just published by Faber. This is brave and shining poetry, timeless and utterly contemporary.Plus Robin and Peter dip into a verdant world, read the Imagist poem, Green, by D.H. Lawrence and, via Chroma by Derek Jarman, find ourselves on the shingle at Dungess by the nuclear power station. Robin talks breezily about Vanitas, the fleeting nature of life, and how she arranged the still life on the cover of her new book, The Mayday Diaries, skull and all...Support the showPlanet Poetry is a labour of love!If you enjoy the podcast, please show your support and Buy us a Coffee!

Dan Needham is the latest player to reveal more about the Congleton Town squad in our teammates quiz. There's reaction from Richard Duffy after the 1-0 win against Wythenshawe Town and Moorlands Radio's Richard Scott also discusses the season so far. Plus, Congleton Town Ladies coach Martyn Cooke and captain Holly Clark share their thoughts ahead of their final game of the season. Hosted on Acast. See acast.com/privacy for more information.

I'm joined by Richard Scott and Polly Moseley from the Scouse Flowerhouse to explore the transformative power of community gardens. They share insights on using wildflowers to create vibrant, biodiverse spaces that benefit both people and wildlife, as well as the challenges and rewards of managing community green spaces. Listen on to discover how their work is weaving nature into urban communities. Links www.scouseflowerhouse.com Other episodes if you liked this one: If you liked this week's episode with Richard Scott & Polly Moseley you might also enjoy this one from the archives:  1. Episode 275: Community Gardening Synopsis: This episode delves into the world of community gardening, exploring how shared green spaces can foster community spirit, provide fresh produce, and promote environmental stewardship. The discussion highlights the benefits and challenges of managing communal gardens and offers insights into starting and sustaining such projects. 2. Episode 173: Sharing and Borrowing Gardens Synopsis: In this episode, host Sarah Wilson speaks with Joyce Veheary, founder of Lend and Tend, an initiative that connects garden owners with individuals who lack their own gardening space. They discuss how this platform facilitates the sharing and borrowing of gardens, promoting community engagement and making gardening more accessible to everyone. Please support the podcast on Patreon

Congleton Town player-manager Richard Duffy speaks to Moorlands Radio's Richard Scott after the Bears beat local rivals Kidsgrove Athletic on New Year's Day where this week's fan away day also comes from. Plus, non-league football writer Andrew Simpson shares why he picked Richard Duffy as his Non-League Paper Manager of the Year for 2024. Hosted on Acast. See acast.com/privacy for more information.

This is part 3 in our Advent series called The Fire Inside. You can watch the digital service on YouTube: *coming soon... If you had questions during the message, text them to 567-246-0807 and we will contact you to discuss your thoughts. You can also join us in person every Sunday where we welcome your questions and discussion. *Closing Song is "O Come, O Come Emmanuel" - Matt Maher -Lyrics: Matt Maher, Ike Ndolo, Hank Bentley, Richard Scott, John Mason Neale, Henry Coffin -Copyright: © All Essential Music, Bentley Street Songs (Admin by Essential Music Publishing) Valley of Songs Music (Admin by Capitol CMG Publishing) Richard Scott Designee Performed by the WCC band with permission under CCS License #4935

Hwæt a Movie returns with Beowulf: Prince of the Geats! Given how hard this one is to find, we'd be surprised if any of you have seen it. Released in March 2007, shortly after SYFY's Grendel and ahead of Robert Zemeckis's Beowulf, this Scott Wegener-directed indie film dives into the epic tale with a unique take on the hero and his legendary battles. And while the film's limited budget and production constraints might be apparent, its dedication to the original text shines through. Making the film more charming and admirable is the fact that the production team and actors all worked for free on this passion project. All proceeds from the sale of the DVDs for Beowulf: Prince of the Geats went to aid both the American and Norwegian Cancer Societies. Get a sense of the film by watching the trailer here. The film stars both Jayshan Jackson and Damon Lynch III as the younger and older Beowulf. Wegener's decision to depict Beowulf as the son of an adventuring African fisherman offers some interesting possibilities and an approach to the character that we haven't seen yet. It's also one of the few film adaptations to follow Beowulf home to Geatland after his time in Denmark. As always, our episode includes an exhaustive summary of the film, a Q&A discussion, and our final ratings. How do these versions of Beowulf, Grendel, and Grendel's Mother stack up against those we've seen before? And how does this quirky, low-budget film score on its fidelity to the source material and its overall entertainment value? As the length of the episode might suggest, we've got a lot to say about this one. This was a delightful film to unpack, and we hope you enjoy hearing about it as much as we enjoyed discussing it. If you're interested in reading more about Wegener's decision to cast black actors to play Beowulf and the responses it prompted, check out the following articles and discussions: Clark, David. "Race/Ethnicity and the Other in Beowulf". In Beowulf in Contemporary Culture, edited by David Clark, 31-50. Cambridge: Cambridge Scholars Publishing, 2019. Nokes, Richard Scott. "Beowulf: Prince of the Geats, Nazis, and Odinists". Old English Newsletter. 41, no. 3 (2008): 26–32.   Listen to our overview, watch the trailer (or find the film if you can), and let us know what you think on our social media: Sagathingpodcast on Facebook Sagathingpodcast on Instagram Sagathingpodcast on Bluesky Or join others like you on Saga Thing's unofficial official Discord

Researchers are hoping take advantage of new gene technology regulations as soon as possible. The Government's planning to introduce legislation this year to let researchers develop and commercialise gene tech products - outside laboratories. AgResearch Science Team Lead Richard Scott says taking it out of the lab will speed progress and reduce red tape. He says projects are already under way on genetically modified grasses. "We've already put forward an application to trial that in New Zealand - and we've got another couple lined up and ready to go." LISTEN ABOVESee omnystudio.com/listener for privacy information.

Genomics has changed considerably over the past 10 years, and we are now exploring how to integrate it into routine healthcare. In this episode, our guests reflect on this evolution and discuss how the key learnings from the past 10 years can shape the genomics ecosystem of the future. They highlight the importance of partnership across teams, organisations and participants, emphasising the importance of keeping participant and patient benefit at the heart of research, whilst also addressing the ethical and safe storage of patient data. In this episode, our host, Helen White, who is the Participant Panel Vice-Chair for cancer at Genomics England, speaks with Dr Rich Scott, CEO of Genomics England.   "Our goal is to ensure that everyone can benefit from the advancements in genomics, but this requires collaboration across disciplines and a commitment to ethical practices in managing and sharing genomic data."   You can read the transcript below or download it here: https://files.genomicsengland.co.uk/documents/Podcast-transcripts/How_can_we_work_in_partnership_towards_a_new_era_of_genomic_medicine_and_research.docx Helen: Welcome to Behind the Genes.  Rich: There's a whole new era I see coming in terms of the therapies that are directed at the causes of genomic conditions, both in rare conditions and in cancer, and thinking as we do that, about how we structure the system to generate evidence, and to respond to it, and have a conversation about what the right balance of evidence for patients to make a choice about their own care.  Helen: My name is Helen White and I am the Participant Panel Vice Chair for Cancer, at Genomics England. On today's episode I'm joined by Dr Richard Scott, Chief Executive Officer for Genomics England. And today we'll be discussing Richard's recent appointment as CEO, lessons learnt from the last ten years in the evolution of genomics in healthcare, and how these learnings will be taken forward in the next ten years. And we'll also visit the importance of keeping participant and patient benefit at the heart of research, as well as the ethical and safe storage of patient data. If you enjoy today's episode we would love your support: please like, share and rate us on wherever you listen to your podcast.   Before we dive into the interview with Rich, I wanted to take a moment to share my story and tell you a little bit about myself. I have been a member of the Participant Panel at Genomics England since 2018. It was the year before that when I was diagnosed with endometrial, or womb cancer, and was offered the chance to join the 100,000 Genomes Project, which felt like something positive at what was otherwise quite a scary time. It turns out that I have something called Lynch syndrome, that's a genetic condition that increases my chance of developing certain cancers, particularly womb and bowel cancer, which is actually a really useful thing to know as there are things I can do to reduce my chance of getting cancer; things like having regular colonoscopies and taking daily aspirin. I have now been on the participant panel for six years and one year ago I was appointed as Vice Chair for cancer. This is a new and developing role and I am excited to have so far helped recruit more people with lived experience of cancer to the panel and to be assisting Genomics England with connecting to organisations that advocate for people whose lives have been touched by cancer.   So that's enough about me. I am delighted to be joined today by Richard Scott, and I am very much looking forward to our conversation. Welcome, Rich.   Thank you. So Rich, you've recently been appointed CEO of Genomics England. Can you tell me a bit about your background and what brought you to this role?   Rich: It's a really good question and it's one that doesn't have a really very simple answer. I guess what it boils down to is I guess I've always had an interest, even as a child, for whatever reason, in genetics and genomics. I have also then always been drawn to things where I can have an impact and particularly the impact in healthcare and that's what took me to being a medical student. And I guess it's that combination of that particular interest in genetics and being able to see, even when I was at medical school I qualified in 2000 that this was an area of medicine that was going to be really important in the future. And then as I trained, as I did a PhD and as I saw the technology develop and change and then when I saw the UK government and the NHS investing in genomics in a really foresighted way, I found myself eight or nine years sitting at Great Ormond Street as a consultant in clinical genetics where I still practice, I still do one clinic a month there as a clinical genetics consultant seeing families with rare conditions.   But I could see when Genomics England was established that this was something, as I said, really foresightful where we could really collectively across the country make more of a difference together in terms of patient and healthcare outcomes. So I joined GEL eight or nine years ago initially in a subject matter expert role, and really found myself the more time it passed, understanding how working in my role at GEL and helping GEL be a really productive part of what is a busy genomics healthcare ecosystem in the UK, we can make a big difference, and that's the thing that just wakes me up in the morning, is realising how much there is left to do, being proud of the stuff we've done, the difference we've made to participants in our programmes already, but realising that many of those still need our support to do better and the big distance left to go before we really deliver on I think the long-term promise of genomics, and I feel my mixture of skills and experience make me really excited to be in the middle of that.   Helen: Thank you. Yes, it sounds like you've brought many skills and experience, and interesting to hear that as a child you already had that interest in genetics and where that's taken you. Can you tell me what being CEO Genomics England means for you? What are your aspirations for your first year in this position?   Rich: Well, I guess, as you can tell, I'm really excited to take on this role. As I said, as a doctor I'm always focused on the impact for patients and our participants and ultimately it's the broader health of the nation. And the role I see Genomics England playing and being able to play in the future, sort of building on that, the leadership position the UK's always had in genomics – you know if you look back to the discovery of the structure of DNA, the invention of sequencing technologies and also the clinical implementation coming from that government investment and the NHS investment, what excites me most about GEL is that we can be there, playing a critical role alongside others in that ecosystem, whether that's in the NHS, whether it's our participants and the patients who we're aiming to support academia and industry, to create a whole that's greater than the sum of the parts, and I genuinely feel that the UK remains uniquely placed to live out that potential that genomics has, engaging in the questions, not just you know, the scientific questions of: what could genomics test for? Or, how could this be implemented and is it cost-effective?  But also being able to have the nuanced conversation of what we all and our participants in the public and general, expect in terms of the care we receive or how our data is looked after, and getting that really balanced view on how we chart a path forwards where we can really see big differences being made in the future, and I think always being honest to ourselves about where we are today and that things don't come in spotting some position a long time in the future that we want to navigate to, but also being really focused on the here and now and what is possible and what is evidenced, and what the next set of evidence or discussions or conversations in the public we need to have to help navigate ourselves there and that's where at the moment our focus at Genomics England is both being very clear sighted on where Genomics could go, and also thinking very clearly about where we are today, and so very much at the moment for us it's about focusing on the life service we offer to the NHS and we're really proud to be part of a world-leading whole genome sequencing service, the first national health service in the world to be providing that in the context of cancer and rare disease, and so offering and providing our service that contributes to that.   Supporting researchers so that we can keep the flow of discoveries coming and also for example, making sure that our participants in existing programmes continue to get new answers as the science evolves. So, the last year more than 2,000 families had new findings fed back because of new knowledge that's accumulating, keeping that flow going. And then we've got three big research initiatives going on at the moment where we're really focusing on delivering around them. We've got a diverse data initiative where we're really focused on making sure the research library, the National Genomic Research Library, our participants are representative of the UK population, so the discoveries that we're supporting are relevant to everyone; our cancer initiative which is exploring the use of new sequencing technology in the context of cancer, and also looking at the use of image data and other modalities of data, alongside generic data to drive new discoveries.   And then the third initiative is our newborn genomes programme, where we're asking a big question through a research study to generate evidence to ultimately answer the question: should every baby when they're born be offered whole genome sequencing? Most pressingly to improve and broader the range of conditions that we can look for that are severe and treatable. So, this year we're very much focused on delivering on those promises that we've made to our participants and our partners and through those programmes and very much with an eye to the future thinking about what we need to change in terms of the use of underpinning technology, so that we know that we've got the potential to scale, to think about the broader use of genomics in years to come as evidence evolves.   Helen: So Rich, there have been many advances in genomics in the last ten years. What do you think are the big lessons from those last ten years, and what do you think the next ten years will look like for the genomics ecosystem, what impact will this all have on healthcare as we know it?   Rich: So, genomics has changed extraordinarily in the last ten years thanks to shifts both in the technology, particularly the sequencing technology but also some of the computing technology that's there to deal with the scale of data. Ten years ago we were talking about the 100,000 genomes project and beginning the project itself, but it was still very early in the use of whole genome sequencing, that's gone from something where the big question around the 100,000 genomes project was: can this technology be used in routine care in cancer and for rare conditions, and if so, how do we do that?   And we've learnt both I think about that specific question and as I mentioned, we're enormously proud to be part of enabling the NHS whole genome sequencing clinical service, so that has entered routine care. I think along the way the biggest lesson for me is actually one about this being about partnership and about working as a team across many different organisations and with our participants, and recognising that this isn't just about one set of questions, or it's not just about clinical or scientific questions, it's about joining everything up together back to that point around, so a discussion about what people expect – this is about doing stuff together and learning often quite complex lessons about practicalities is one things, for example, one of the really big lessons we learnt around the use of whole genome sequencing in cancer are just practical lessons about handling of tissue samples and the need to make sure the right fridges are available on the right corridor of a hospital, with plugs available to plug them into, through to questions around, as I say, people's expectations around how their data is stored, which it's used for, which again there's really strong precedent for, and as we explored, different uses of genomic technology, we shouldn't just take those previous answers for granted, we need to make sure we validate and check with people what their expectations are.   So I think that's the big one for me is sort of the number of different angles with which one explores questions and the fact that this is very much about doing it together. I think just one other piece which is so easy for us here to take for granted is that doing things at national scale with national scale investment from government, from other funders and from the NHS is absolutely critical and when you look across the world, we are in an extraordinarily privileged position here in this country because of that investment and because that investment recognises the need critically to join clinical care and research in a whole, where you recognise that you're doing multiple things at once, but joining them up rather than them being two worlds, is really, really critical, and we're really lucky to be able to do that at national scale.   So then thinking about what the next ten years might look like for the genomics ecosystem, I think lots of those things continue, so I think national scale and the need for ongoing investment to keep up our position at the forefront in terms of answering these big questions about the use of genomics in healthcare, and to where the evidence supports their implementation to roll them out and keep that link there between healthcare and research, and so making sure the systems talk to each other and I mean that in a digital sense as well as a human sense is absolutely critical.   And then, so in ten years' time what are the areas of healthcare that will have been impacted, or could have been impacted by genomics, I'm really pleased that we're doing a better job for families with rare conditions and people with cancer than we were ten years ago, I think there's a long distance left to run even in those settings for us to do better and to continue to learn, so we expect our major focus to continue to be in those areas where we know they can have an impact and there's more to do. We also then have the different areas where if the evidence pans out to support the use of genomics or if we can implement systems that can support it there can be a big sort of area of growth. For example, our newborn genomes programme is asking questions and developing evidence so that in the future policymakers can decide should that become part of routine care, and I think that's something that could have become part of routine care in the next ten years if the evidence supports it and if that's something that the public support.    If I were to pick one other area where there's a real potential for growth in the coming handful of years it's in something we refer to as pharmacogenomics. What that means is looking at your DNA code (genomics) to help make decisions about prescription of medicines and sometimes that's about avoiding these medicines in people who are at a higher risk of having an adverse reaction, or it's about tailoring the dose because of something about for example the way the person metabolises, chews up, the medicine and so can influence how much dose they need. That actually has an enormous potential; we all have variations in our DNA code that influence how we respond to or metabolise medicines. If you look across primary care, GPs and so forth, primary care physicians and in secondary care, hospital care, I think there's good evidence that actually probably half of all appointments, interactions in those settings, if you were to have DNA data available that could influence how prescription choices are made; sometimes that's about knowing that you're doing the right thing, giving the normal prescription, but sometimes it's about modifying it, that's an area where I think there's a real potential for growth and that's an area that the NHS also really recognise and we're exploring ways in which we might look into that and think about how that might be implemented, because actually a lot of the questions there are about how you make sure the right data, the right information is available to clinical teams and patients at the time that prescriptions are being made.   There's also real potential more broadly in thinking about more common disease settings, there's lots of work going on from various research studies looking at the value of what people sometimes refer to as polygenic risk scores or integrated risk scores, where we use genomics as an element of estimating risk for common diseases like heart disease or cancer, that's something where the evidence is being worked on and is developing, I think we'll see a lot of evidence come out in the coming years and I think that will then influence how we implement genomics to help as part of that risk estimation process, which is routine now in GP practices where you go for an NHS health-check they do it with lots of complicated stuff, at the moment not genomics, and we'll see how that plays out in the years to come.   So I think there's enormous room for growth where genomics where at the moment it's making an important difference to people with certain conditions that we can do better on. In the future I see it becoming very much more part of the routine day to day of healthcare. As we make that transition there's lots to work through about the evidence, the order in which that's done and the way in which we, for example, store data, and make people part of the choice about how their data is used and what I'm really excited about in Genomics England is the role we play in the middle of that, bringing our particular expertise around what we call bioinformatics, which is sort of managing genomic data at big scale, particularly national scale to support healthcare and research, generating evidence that can help inform policy, and also critically drawing things together into the conversation amongst different players in the ecosystem and participants in the public so that we can not just think about evidence in a sort of terribly scientific way but we think about it in the round.   Helen: That's really interesting to hear you speak a lot about getting that evidence because that's critical, but that takes a long time doesn't it, so for example with the generation study, the newborn study it's really important to measure the benefits of that if you're testing young babies, newborn babies for diseases that if you pick up a condition that condition can be treated and something can be done about it early rather than poor parents going through this diagnostic odyssey, but also it's that balance isn't it with not leading to any harm, so if a number of parents come out of that thinking their baby might get a condition and it never happens there's potential there isn't there. But I think in terms of the public understanding of how long it takes to get evidence and everything else that needs to go on in the background I don't think it's always particularly clear that that's a massive process that has to be gone through and there's a lot of work going on behind the scenes – you can't just do these things.   I think as patients/members of the public we're eager to get on and for change to happen and things to be better but it's a big, big process, but also good to hear that you talk about it being a collaborative approach, it's not just Genomics England, it's the NHS, it's members of the public and patient voices, it's other organisations working in partnership, it's a big undertaking.   Rich: No, it is and I think that one of the words you used there was impatience, and I think that's healthy and important to recognise, it can be easy, particularly for example as a doctor, sat in a clinic room to accept the status quo, and at the same time, one needs to recognise the complexity of the questions, the balance, the need to generate high-quality evidence to inform those opinions and I think combining both that sort of impatience and dissatisfaction with the status quo, and that mind-set about thinking really thoroughly and collaboratively about the right evidence that is needed to change policy.   Helen: Yes, really important that those patient voices are there from the beginning, from the planning of obtaining this evidence and that you're measuring the things that matter most.   Rich: One of the areas where I think we've seen that play out, another area where I really see the potential for growth in the future is much more genomics-enabled treatments. We and you and the participant panel have helped us think about there's a whole new era I see coming in terms of the therapies that are directed at the causes of genomic conditions, both in rare conditions and in cancer and thinking as we do that about how we structure the system to generate evidence and to respond to it and have a conversation about what the right balance of evidence for patients to make a choice about their own care, but also policymakers to make choices about funding, decisions and safety decisions, is really important and we've been supporting to a wider work in cancer in the UK called the Cancer Vaccine Launchpad, and likewise we're part of something we call the Rare Therapies Launchpad, where in those two areas we're exploring that, and that's another area I think of real potential in the coming years, and also real nuance as we construct a way of navigating that together and making the most of the potential, but not just sort of rushing in and pretending we know all of the answers at the outset.   Helen: And those launchpads are of particular interest to participants in the wider patient population, there are a lot of people and children with rare, ultra-rare conditions who are desperate for treatments that just aren't available right now, equally for cancer patients there's a big need isn't there for more effective treatments, fewer side effects, that target that person's particular cancer, so it's good news I think for the wider public.   It does seem that innovation and partnerships are crucial to Genomics England's activities so how does Genomics England ensure that participant and wider patient benefit are at the heart of these activities?   Rich: I think one of the really important things is actually governance is sometimes a boring word, sounds like it, but I think thinking about how we've structured the organisation and placed you, as the participant panel, as part of our governance to make sure that when we're thinking about for example access to data in the National Genomic Research Library, participants are sort of driving those decisions, it's an independent committee that makes those decisions with representation from our panel. One of the things is thinking about the governance and making sure that you as our participant panel hold us to account for the decisions that we're making, which I think is really critical.  I think then also as we've learnt a lot over the years, not always getting it right, about how we make sure that participants, or potential participants in the public are involved from the outset in the design of programmes because it always helps. I think certainly before I joined Genomics England I think I would have been unsure about the best ways of going about that and that brings with it sometimes a nervousness. I think the main advice I would say to people listening is to have confidence that just getting stuck in and have conversations is the way to do it. There are then also all sorts of expertise that we've really benefited from being to bear in terms of ways of doing that engagement work and that will come; the first thing is to have the confidence and the desire to put that at the centre of how you decide where your focus should be and how you design programmes.   Helen: I think Genomics England has been very successful with that by integrating that patient voice from the very early days and here we are what eight years on I think now, and yes, hopefully we'll be there for some time to come yet, as long as Genomics England exists. So Rich, with more and more health data being stored, how do we ensure that this sensitive personal data is stored and used safely and ethically across the genomics ecosystem. And actually while we're on this question, can you just explain what genomics ecosystem means, because we use that term I think quite a lot, but I think it's not necessarily understandable to the wider public? Rich: What I mean when I talk about it is I mean the mixture of different people, whether that's sometimes organisations, us, Genomics England, the NHS, the NIHR, National Institute for Health Research; industry partners whether they're people who are from pharma companies or from biotech, academic researchers, participants in programmes – everyone who comes together to work on genomics in the UK and a bit like the word as it's used in biology, it's a sort of busy ecosystem with all sorts of people playing their own role and then working together, and so I think it's a really important thing to recognise that we're part of that and in fact it's one of the things I love most about my role at Genomics England is thinking about all of the different partners that we need to work with and to those outside it I think it can also be a bit intimidating, because it's hard to keep up with who on earth everyone is. So then thinking about the question of how we make sure that data's stored and looked after and used in the ways that people expect and safely and so forth, I think that's absolutely at the heart of my role and our role. And I think one thing is actually always sort of starting at the: why are we doing this? What benefits are we seeking to bring to people? Is that what they expect? What have they signed up for if you like? But that's in a research study or when they've decided to say yes to having a particular test, which is the same in any part of medicine. And if we use that to drive our decisions, that's what's so critical. And so that's where thinking about programmes we run, and also the things that we think might be worth something that we should prioritise in the future is always first driven by the benefit that you might be bringing, weighing up the costs and the potential downsides and harm that might be caused by the use of genomic data in that way and that's what should always drive things, and there isn't a one-size-fits-all, you know, genomic data should be used and stored in this way and that's one of the things that I think making sure that participants and the public are at the centre of the conversation is absolutely critical, it turns out that genomic data is very much like health data at large in many senses and it's very precious for those reasons. It is also special in a few ways. One of the ways that's sort of peculiar if you like is that pretty much the DNA sequence, the genome, that you're born with, is the same one that you hold throughout your life, that's different from say if you do a blood count or something that varies for various reasons over your life and most things in medicine do change quite meaningfully over a much shorter time period. One of the things about the DNA code: A) it makes it more precious because it's very much about you, your whole life; also it makes it more useful and reuseable in many ways, so one of the things that we think about a lot more in genomics is about the storage and reuse of data on an ongoing basis through the lifetime. And I do think that that model in certain settings and potentially more broadly as evidence accumulates, may well be the path that we take forward where you consider your genomic data part of your health record where it can be used and reused. And what we need to do is explore why you would in the first case generate someone's DNA sequence, and what sort of sequence, is it a whole genome or less than a whole genome? What would you use it for in the first place when you first generate it? And what other uses could there be to support the healthcare and have you involved them or the public more generally in decisions about how it's used? Because we do, as I said, see the potential for genomics being just becoming part of the fabric if you like of healthcare, good healthcare, the best healthcare.   Linked to that is the point on research as well, like where people are happy for it, holding their genomic data and understanding how that impacts on longer term health outcomes, something we'll continue to learn about for years and years. So I think the first point is about focusing on the why and whose data it is, one's own genome belongs to you, it doesn't belong to anyone else, what people are happy with and consent to and expect and then always holding that in mind as one makes the choices is critical. I've talked about how we think the governance and the involvement of the participant panel is really critical for that as well. And then it also comes down to doing in various ways, the job that people would expect in terms of, for example, that safety piece, using the very latest tooling to make sure that it's held in a secure way, that it's backed up so that it won't be lost etc. and bringing sort of the right, very good minds around some of those more technical questions, but always with the expectations of the people whose genomes they are in mind and to say are we living up to their expectations, are we doing what they would expect?   So, Helen, I wondered if I could ask you a couple of questions. The first one I wanted to ask is what you're hopeful for in the coming years as a participant panel member?   Helen: Thank you. I've actually already posed these questions to some of the other panel members, so I'll try and make sure I include their responses here as well as mine, but I think it's important to hear from everybody, not just me, Rebecca Middleton and Emma Walters have recorded their responses as well. I think the four main things that panel members are hopeful for is the coming years, the first is equitable access to whole genome sequencing, basically everybody who needs whole genome sequencing should get access to it regardless of where they live, their income, ethnicity or disability, so that's something that we're hopeful will get better over the years.   We know this is essential to improving healthcare, to improving outcomes for patients and generally for sort of greater inclusivity and in genomic research, we want as well as Genomics England, the data is the National Genomics Research Library to be representative of the population as a whole, not just the people who 1) are offered, and 2) agree to have their data in the library. And also, obviously the more data that is held in that library, the more opportunity there is for research across those rare and ultra rare conditions and rare and less common cancers, where it's all about numbers, you need numbers of sets of data in order to draw things together and make conclusions to look for patterns.  And the other thing which I guess comes more under the umbrella of the NHS is that the panel is quite keen, they want everybody who's undergoing genomic testing to receive good support and after care, I think regardless of whether that testing is via the NHS or as part of a research study, sometimes it will be both, but that's for the patients at the coal face that is obviously critically important.  The second, I think broad theme, coming from the panel members' responses is that I think you've mentioned this already, is increased understanding of genomics amongst the general public is really important – there's a need to demystify genomics and to generally improve public awareness of its benefits and to get those conversations going around its regulation and its ethical use, but to do that you need to get meaningful engagement from a wide range of people, you know, that's not always straightforward, there are lots of challenges there, it's all about prioritising inclusivity, accessibility, to make sure you get diverse views and perspectives on genomics and on genomics research.   The other thing that came out very strongly from the responses which we have talked quite a bit about already is about this individualised healthcare. I think we as a panel are very hopeful that there will be this shift towards treatment strategies that are tailored more to the individual and their specific health condition, rather than a one-size-fits-all approach, we want effective treatments that will minimise side effects but also through the use of pharmacogenomics, to make sure if there's a risk of a severe, sometimes life-threatening side effect that that can be identified and that individual doesn't have that treatment either at all or has a lower dose, so it's not so toxic.   And let's hear from Emma who talks about this.  Emma: My hope is that we move to a truly individualised healthcare system and I'm really excited to see how in particular pharmacogenomics changes the healthcare landscape. For a long time we've gone with a one-size-fits-all approach, and that's easy to deliver on a large scale basis that the NHS works on, but we know fundamentally that's not how patients work, so to be able to consider individualising medication and knowing which won't work, interests and excites me.   Helen: So the panel is also very hopeful about the development of those innovative therapies, and you talked about the rare therapies launchpad and the cancer vaccine launchpad, because those offer real hope for treating previously untreatable conditions and generally improving accessibility to treatments. And we're also hopeful that there will be a much better understanding of diagnosis of cancer, through things like the multi-model programme, because although there's lots and lots of research going on with cancer there's still a long way to go to have more effective treatments and to improve diagnosis of cancer.   And then just finally just in response to your question, patient and public involvement, this is what the participant panel is all about, we are a group of individuals whose lives have all been touched by either a rare condition or by cancer currently, either we've had that condition ourselves or it's affected our loved one, and we do bring these diverse views and perspectives to Genomics England and I think we have a crucial role in influencing its decisions about what it does with participant data and who has access to that data. It's critically important that Genomics England listens to what matters to the people whose data it holds and who do that, as Rebecca here explains.  Rebecca: Genomics is a fast-moving science and it has the impact to change lives and healthcare for future generations, but genomics is a science of people and therefore the only way you can truly understand the limitations and opportunities of it is to talk eye to eye to the very people it will impact, and not everyone will agree on everything. But how we understand genomics and its power to transform healthcare, our own and that of our children and the ones we love, can only progress at the pace of the people that it will benefit. It's a simple equation but it's not maths and indeed not science: we are all different and unique, our emotions, experience and history will be wrapped up in our viewpoints and thoughts, and that's where the panel comes in, representing and advocating for the very many different voices of genomic healthcare, ensures Genomics England is stronger, healthcare design is more meaningful and research is more impactful.  I have no doubt that the panel of the future will continue to be heard and understood at Genomics England, and I hope it continues to grow to reflect more diverse voices and experiences and continues to be the people inside the science.   Helen: Finally, the panel is also hopeful for increased public and patient involvement in genomics research, this is integral for shaping research both academic and commercial, it helps with identifying research priorities, developing new treatments, basically getting that voice of the patient in there to tell researchers what's the most important and what matters to them.  Rich: So another question Helen, how do the panel feel about the changing genomics landscape? Helen: A good question and I think overall it's a balance between excitement and hope on the one hand, and a bit of apprehension and caution on the other. So the panel is really excited about the advances going on in healthcare, we're entering an age now where we're promised a much more proactive, as opposed to reactive approach to healthcare. You were talking earlier Rich, about having your genome sequence, and this is something that you have for life, it's like your passport, your fingerprint, so from infancy to old age you've got this data which is held somewhere which holds so much promise of predicting if you might develop a disease, whether you might react badly to a drug, so ultimately it offers great potential to improve outcomes for patients, their families and the NHS. Again, we spoke earlier about this holds so much promise for producing the diagnostic odyssey that so many parents go through when the children are born with a condition that doesn't have a diagnosis, potential to diagnose things like cancer a lot earlier where it's more treatable and to prevent disease as well, I know that's something Genomics England isn't specifically looking at, but through screening programmes, using things for example like circulating DNA which may be able to pick up that there are things going on and picking things up earlier means that those things can be dealt with earlier.  I mean thinking of my own personal example, I know I have Lynch Syndrome, I know that I am at risk of developing bowel cancer now, but that means I can do something about it. So I have my colonoscopies every two years, I take aspirin every day because that reduces my chance of getting bowel cancers and I'm much more symptom-aware, so having that knowledge up front is very helpful in being able to move forward and reduce my chance of getting an advanced cancer.  The panel is also very excited about the ongoing collaborations and the novel therapies that are being developed through the rare therapies launchpad, these offer a lot of hope for treating previously untreatable conditions, and improving accessibility to treatments, and obviously more targeted treatments for cancer, you know, we'd need more effective treatments for cancer but with reduced side effects, so that in a nutshell, those are the other positive sort of things that the panel feel excited about. Where they're slightly more apprehensive or concerned, I mean they do acknowledge that there are challenges ahead and there are big concerns about the NHS's ability to cope with increase in demand for genomic testing and particularly worries about education and training of healthcare professionals in genomics, how do they effectively communicate research findings or results to patients if they don't have a broad understanding of genomics?  And then finally, let's hear from Emma.  Emma: I think I'm excited but cautious. I think it's really important to acknowledge that the research being undertaken is groundbreaking and the vast majority of clinicians have very little to know genomics education, and translating these findings into tangible benefits for participants is so very important, and something I think we've really got to make sure we don't lose sight of.   Helen: We talked earlier about awareness among the public about genomics and we do feel that there's a need to drive education forwards, you know but this is challenging, given the rapid pace of developments that we've spoken about, I think even for the panel members who I would say are relative experts in genomics now it's hard to keep up to date, so how do we do that moving forwards? We've talked about security of data, we understand there are moves to link more genomic data sets both nationally and internationally and that clearly has significant benefits because that brings bigger numbers of patients data together, but opens up potential risks in terms of security, so how do we make sure that the security of that data is as good as it is currently when it's held in one pot in Genomics England Research Library.   And just a couple of final concerns that were flagged by panel members, there is some apprehension regarding potential misuse with genomic data by insurance companies; we're given a lot of reassurance about that but there are concerns that could potentially lead to the most vulnerable in society being unable to get affordable cover if they're found to have genomic changes that mean they are at risk of conditions or have certain conditions and there are also concerns about the ethical implications of AI in diagnosis and clinical decision making, you know, AI is obviously a fantastic thing for looking at patterns amongst a big lot of data, but how accurate is it and where does the human come in, in terms of decision making?   So those are, I think, the broad concerns from the panel. I don't know if you have any thoughts on those, Rich? Rich: I think the big thing to say is I think having the participant panel there, you said in the middle of that, become collectively quite expert and you recognise that. Having the ability to have these complex nuance conversations and have people share that and speak directly to us about it I think is the biggest thing – lots of those points there made by the panel, I think both things that we have very much in our mind about things that one needs to balance and focus on, and there are also things that we already talk about which is reassuring I think as well, we talk about with the panel. I think one of the things for us as well is sort of being clear on some of the things where there are really clearly well-established red lines, for example, that point on insurance, but that is very clear and part of our role is making sure that that is there and people can feel comfortable in that context to understand that.  I think the main thing that I would say is thank you to you Helen, and to all of the panel and all of our participants because I said earlier, this is a team thing and you are all very much part of the team and we would not be able to do our jobs in any way, I wouldn't even say effectively, I would say with the relevance, which is the thing that we drive for, the relevance to have impact for people's lives whose data we hold and will hold in the future. And so thank you for being part of the team. Helen: Thank you. And I think thank you to Genomics England for having the foresight to create the participant panel in the first instance, it was there from the get-go and I think a really great opportunity for all of us to be involved in this, to have our voices heard and listened to, so thank you.  We'll wrap up there. Thank you for joining me today and thank you for discussing your appointment as CEO for Genomic England, and your view on what the genomics ecosystem might look like over the next ten years. If you would like to hear more like this, please subscribe to the Behind the Genes, on your favourite podcast app. Thank you for listening. I've been your host, Helen White. This podcast was edited by Bill Griffin at Ventoux Digital, and produced by Naimah Callachand. 

Richard Scott Larson's debut The Long Hallway (University of Wisconsin Press, April 2024) is a lyrical memoir that expresses a boy's search for identity while navigating the darkness and isolation of a deeply private inner world. Growing up queer, closeted, and afraid, Richard Scott Larson found expression for his interior life in horror films, especially John Carpenter's 1978 classic, Halloween. He developed an intense childhood identification with Michael Myers, Carpenter's inscrutable masked villain, as well as Michael's potential victims. In The Long Hallway, Larson scrutinizes this identification, meditating on horror as a metaphor for the torments of the closet.Richard joins host Sara Batkie for a conversation about the masks we wear, the horrors of suburbia, and finding the right home for your work.Richard Scott Larson is a queer writer and critic. His debut memoir, The Long Hallway, was published by the University of Wisconsin Press. Born and raised in the suburbs of St. Louis, he studied literature and film criticism at Hunter College and earned his MFA from New York University.He has received fellowships from MacDowell and the New York Foundation for the Arts, and his work has been supported by residencies from the Virginia Center for the Creative Arts, Vermont Studio Center, Paragraph Workspace for Writers, La Porte Peinte, and the Willa Cather Foundation. He's an active member of the National Book Critics Circle, and his writing has been recognized twice by The Best American Essays.

We're thrilled to welcome the co-writers of Morning Sun and many more incredible tracks to the podcast - Richard Scott and Scott Ralph.  We're excited that Rich has returned to the show after we interviewed him and his brothers Kelvin Andrews and Danny Spencer in 2022. This time we're also joined by their longtime friend Scott Ralph, the final quarter of Robbie's songwriting crew from Stoke-On-Trent.  Scott shares what happened when he was invited to LA to write with Robbie alongside his friends, and recalls some hilarious (and embarrassing!) moments. Rich and Scott have penned lots of swing-style songs with Robbie such as Soda Pop and On The Fence, as well as Under The Radar classics like Super Tony and Underkill.   We hear about UFO hunts and an impromptu Gollum cameo at a BRITS after-party - we didn't stop laughing throughout and can see why Rob loves writing with his Stokie mates.======If there is an advert in this episode details will appear below:============**About Robbie Williams Rewind**Join husband and wife Matt and Lucy, as they rewind through legendary pop star Robbie Williams' solo career. Each episode, they have a guest fan to help us relive Robbie's incredible music and tours.Visit: robbiewilliamsrewind.com to discover more episodes, track listings & photos!Follow: @rewindrobbie on Instagram, Facebook, YouTube, Twitter & TikTok.

On today's episode of The Lives of Writers, Lena Crown interviews Richard Scott Larson.Richard Scott Larson is the author of  the memoir The Long Hallway  (UW Press). He has received fellowships from MacDowell and the New York Foundation for the Arts, and his creative and critical work has appeared in The Sun Magazine, Los Angeles Review of Books, Harvard Review, and other journals and anthologies.Lena Crown is a book editor for us at Autofocus Books. Her essays are published or forthcoming in The Rumpus, Guernica, Gulf Coast, Narratively, North American Review, The Offing, and elsewhere, and her poems have appeared in Bellevue Literary Review, The Boiler, Poet Lore, No Contact, and Variant Lit.____________Full conversation topics include:-- blocking out time to write-- doing residencies-- horror movies and mass-market fiction as a kid-- writing as a critic and with the NBCC-- the role of film in his life and the book-- a crisis of fiction-- memoir vs book-length essay-- the new memoir THE LONG HALLWAY-- gender, sexuality, and horror-- visibility and hiding queerness-- masks and Michael Myers in Halloween-- horror tropes appearing in memoir-- loneliness and observation-- film form-- fear and shame-- the Midwestern suburbs-- epiphany, revelation, and resolution (or lack of)-- examining our own cruelties-- writing about family-- the next book and gymnasts_______________Podcast theme music  by Mike Nagel, author of Duplex and Culdesac. Here's his music project: Yeah Yeah Cool Cool.The Lives of Writers is edited and produced by Michael Wheaton, author of Home Movies.

A new MP3 sermon from Sandown Free Presbyterian Church is now available on SermonAudio with the following details: Title: Service of Thanksgiving for the Life of Thomas Richard Scott B.E.M. Speaker: Rev. Garth Wilson Broadcaster: Sandown Free Presbyterian Church Event: Funeral Service Date: 2/24/2024 Bible: 2 Timothy 4:6-8 Length: 94 min.

‘We've always been here. As long as there has been soldiers, there have been poets. And it's a long sad, venerable tradition.' (Peter Gizzi) A Poetry Review podcast between Richard Scott and Peter Gizzi to accompany the Poetry Review Summer 2022 issue. Richard co-edited the issue with Andre Bagoo. You can read more about their issue here: poetrysociety.org.uk/publications/v…2-summer-2022/ You can buy the issue here: bit.ly/ThePoetryReview Richard Scott's first book is Soho (2018), he guested edited The Poetry Review with Andre Bagoo in Summer 2022. Peter Gizzi's recent books include, Now It's Dark (Wesleyan, 2020), Sky Burial: New and Selected Poems (Carcanet, 2020), Archeophonics (Finalist for the National Book Award, Wesleyan, 2016) and In Defense of Nothing (Finalist for the LA Times Book Award, Wesleyan, 2014). His honours include fellowships from the Rex Foundation, the Howard Foundation, the Foundation for Contemporary Arts, and the Guggenheim Foundation. He has twice been the recipient of the Judith E. Wilson Visiting Fellowship in Poetry at the University of Cambridge. In 2018 Wesleyan published In the Air: Essays on the Poetry of Peter Gizzi. His most recent collection, Fierce Elegy, is available in the Wesleyan Poetry Series in the US, and will be published in the UK by Penguin in July 2024. Music credit: 'A very minimalist improvisation' by Circus Marcus

Recorded by Richard Scott for Poem-a-Day, a series produced by the Academy of American Poets. Published on January 3, 2024. www.poets.org

It sadly wasn't to be for the Bears as they exited the FA Vase in the third round. Hear the fan view from the supporters coach and also the reaction from Richard Duffy. We'll also hear from Moorlands Radio's Richard Scott on what it's like covering Congleton Town. Hosted on Acast. See acast.com/privacy for more information.

This episode explores the significance of digital twins in the construction industry, expanding into various other sectors. The conversation with Anand Mecheri and Richard Scott covers the evolution, application, and future potential of digital twins, highlighting the transformative impact of this technology. Episode Highlights: Guest: Anand Mecheri CEO ndBIM Virtual Building  Richard Scott Chief Partnership Officer  at Twinview Limited Role of Digital Twins in Construction: The transformation from simple digital models to complex, intelligent systems. Application across various industries, including construction, healthcare, and urban planning. Evolution of Digital Twin Technology: Transition from traditional methods to data-centric approaches. The importance of data quality in digital twin implementation. Challenges in Digital Twin Adoption: Overcoming industry resistance and changing mindsets. Integrating digital twins into existing workflows and processes. Operational Focus and Real-time Data Usage: Using digital twins for real-time performance monitoring and optimization. The role of digital twins in achieving net-zero energy goals. Interdisciplinary Collaboration and Stakeholder Engagement: The need for collaboration across different project stages and stakeholders. Challenges and strategies in fostering industry-wide adoption. Future Outlook and Economic Impact: Prospects of digital twins in driving innovation across sectors. Economic opportunities presented by the growth of digital twin technology. Data Management and Analytical Capabilities: The central role of data in driving digital twin efficiency. Leveraging analytics for informed decision-making. Integration with Smart Cities and Urban Planning: Digital twins in the context of smart city development and urban planning. Potential impacts on city-scale infrastructure and management. Industry Evolution and Continuous Learning: Adapting to rapid technological changes in the construction industry. The importance of continuous learning and skill development. The critical role of digital twins in the construction industry and beyond is unmistakably transformative, signalling a shift towards more efficient, data-driven methodologies. Evolving from basic models to complex, intelligent entities, digital twins are pivotal in enhancing efficiency, fostering innovation, and driving industry-wide change. Their impact, spanning from operational optimization to net-zero energy goals, requires embracing technological advancements, fostering interdisciplinary collaboration, and continuously adapting to new challenges.

We sit down with Richard Scott, Author and Publisher and past Licensing Coordinator for the NHLPA to discuss the evolution of sports card media, rewriting the rookie card rules, criteria for rejected sports card images, how the card companies and card shops adapted to the changing rules, the impetus for his many books and who the hobby has to thank for the OPC brand's continued existence since 2005 as well as the history of the Charlton Price Guide and more, so join us live and bring your questions and comments as they will be in play. Leighton Sheldon of Just Collect and Vintage Breaks joins for the "Vintage Spotlight" segment as well. Buy RIchard's books on Amazon here: https://www.amazon.com/stores/Richard-Scott/author/B0C4XQ4KQ7 Saturday October 28 @ 7:00pm PST / 8:00pm MST / 9:00pm CST / 10:00pm EST #sportscards #thehobby #o-pee-chee At the time of this livestream, Sports Cards Live and/or Jeremy Lee is partnered with: - TAG Grading - Sport Card Expo - Center Stage App - Just Collect - Veriswap - PWCC Marketplace - MC Sports Cards - LGC Auctions - Slab Sharks - 90's Auction - Iconic Auctions - REA Auctions --- Support this podcast: https://podcasters.spotify.com/pod/show/sportscardslive/support

Jordan Sollof is joined by Richard Scott, chief medical officer, acting CEO and soon to be the new interim CEO of Genomics England, to chat about the work the organisation does and how AI fits in ahead of speaking at the inaugural Digital Health AI and Data next week. Scott details his background and journey to Genomics England before explaining what the organisation does and the projects they are working on, including the Newborns Genomes Programme. He then highlights the importance of AI and how it can change the genomics landscape for the better and looks head to his session at Digital Health AI and Data, where he will be a keynote speaker alongside NHS England's Dr Claire Bloomfield. The inaugural Digital Health AI and Data conference will take place 30-31 October at the Business Design Centre in London. Registration is available here. The session featuring Scott and Bloomfield, titled ‘Keynote: transforming healthcare through data and research', will take place on Day One of the event at 9.30am on the Data and Research Stage.  

According to the fossil record, ancient humans usually had straight teeth, complete with wisdom teeth. In fact, the dental dilemmas that fuel the demand for braces and wisdom teeth extractions today appear to be recent developments. So, what happened? While it's nearly impossible to know for sure, scientists have a hypothesis. G. Richard Scott shares the prevailing theory on crooked teeth. This TED-Ed lesson was directed by Igor Coric, Artrake Studio, narrated by Addison Anderson, music by Salil Bhayani, cAMP Studio.

Humans evolve over time. Most people do not notice that our jaws are becoming smaller as we evolve. In this episode, George Richard Scott, the Author of The Anthropology of Modern Human Teeth (1997), unlocks the secrets behind the morphological characteristics of jaws. He also provides insights into how the evolution into this modern society negatively changes the apex of human physical stature. George dives even deeper into the Anthropology of Modern Human Teeth and touches on the diet and its impact on our teeth. Get to know more from George as he delves into tooth morphology.Love the show? Subscribe, rate, review, and share! http://thefuturistsociety.net/

When Tracy, a 40-something-year-old Kansas mother of two found Mickey on an online dating site, she thought she had hit the jackpot. He was accomplished, handsome, had his private pilot's license and owned his own real estate company. Within days they were saying I love you and within a month, moving in together. Then, they were talking marriage. It all seemed too good to be true...because it was.Mickey was really Richard Scott Smith, a scammer, cheat, liar and love fraudster who had swindled multiple women out of thousands of dollars, had used multiple aliases and social security numbers. He was also a polygamist, and, at one time, was married to six or more women at the same time. It would take a blog post, a badass bounty hunter, and scores of scorned women to come together to take down the man known as Richard Scott Smith.Show Notes:https://www.sho.com/love-fraudhttps://heavy.com/entertainment/2020/08/love-fraud-richard-scott-smith-update-now-today/This show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/5659010/advertisement

Guest editor of The Poetry Review Summer 2022, Andre Bagoo talks to his contributor Jameson Fitzpatrick. Andre co-edited the summer issue with Richard Scott. You can read more about their issue here: poetrysociety.org.uk/publications/vol-112-no-2-summer-2022/ You can buy the issue here: bit.ly/ThePoetryReview

Support the show for $1/month Chris's Substack - THIN ICE In this episode, Hilliard & Chris chop it up with writers Saeed Crumpler and Richard Scott in this super fun episode. We go IN about the current state of the 2023 WGA Writers Strike and so much more. Tune in for two hours' worth of nothing but industry game! Books Mentioned in the show: Walter Isaacson's STEVE JOBS The Screenwriters Rant Room LIVE PODCAST TAPING! June 23, 2023 2pm-4pm at TCL Chinese Theatre (Hollywood & Highland) Dances With Film FF. RSVP at danceswithfilms.com seating will go fast! Check out the ScreenWriterRR website at www.screenwritersrr.com for information, merch, or our Patreon! Support our podcast through Patreon Remember support is love! We invest countless hours per week to deliver the actionable content that goes into this podcast. Chris Derrick on Twitter Hilliard Guess on Twitter The Screenwriters Rant Room on Facebook --- Send in a voice message: https://podcasters.spotify.com/pod/show/screenwriters-rant-room/message Support this podcast: https://podcasters.spotify.com/pod/show/screenwriters-rant-room/support

This podcast is a commentary and does not contain any copyrighted material of the reference source. We strongly recommend accessing/buying the reference source at the same time. ■Reference Source https://www.ted.com/talks/g_richard_scott_why_do_we_have_crooked_teeth_when_our_ancestors_didn_t ■Post on this topic (You can get FREE learning materials!) https://englist.me/84-academic-words-reference-from-g-richard-scott-why-do-we-have-crooked-teeth-when-our-ancestors-didnt--ted-talk/ ■Youtube Video https://youtu.be/YKmh9-lNQoM (All Words) https://youtu.be/v8DS6lcfgJA (Advanced Words) https://youtu.be/Ol2DNGQhr3E (Quick Look) ■Top Page for Further Materials https://englist.me/ ■SNS (Please follow!)

Richard Scott, an amazing "renaissance man" joined us last Thursday!Business & technology consultant with a 30-year track record of being ‘parachuted in' to countless well-known international companies to deliver/recover difficult projects & programs, rescue them from disaster, or guarantee the success of complex missions.See what he means when he says “Doing what it takes to get it done”! --- Send in a voice message: https://podcasters.spotify.com/pod/show/epic-engagement-adventure/message

In this episode, Hilliard, Chris and writer Richard Scott talk about a lot of fun topics including: the WGA Strike, Structure & Procrastination, the all informing '80 - 20 Rule', British Actors and so much more! Check out the ScreenWriterRR website at www.screenwritersrr.com for information, merch, or our Patreon! Support the show via the Patreon link. Remember support is love! We invest countless hours per week to deliver the actionable content that goes into this podcast. Connect with Us: Chris Derrick on Twitter Hilliard Guess on Twitter Richard Scott on Instagram The Screenwriters Rant Room on Facebook Theme Song by @ThinkDeP --- Send in a voice message: https://anchor.fm/screenwriters-rant-room/message Support this podcast: https://anchor.fm/screenwriters-rant-room/support

Footnotes: Paul Farley; As mentioned at 1 hour 19 minutes https://www.leadinglanguageandliteraturepodcast.com/episodes/paul-farley-poet-and-professor-of-creative-writing-lancaster Soil Inversion case study; https://cieem.net/wp-content/uploads/2019/03/1.-Philip-Putwain.pdf Tony Bradshaw- Restoration ecologist- As mentioned at 1 hour 42 minutes https://www.theguardian.com/science/2008/sep/11/evolution Halewood Triangle- As mentioned at 1 hour 42 minutes https://www.woodlandtrust.org.uk/visiting-woods/woods/halewood-park-triangle/ Gunnersbury Triangle- As mentioned at 1 hour 42 minutes https://www.woodlandtrust.org.uk/visiting-woods/woods/halewood-park-triangle/ Wheeldon Copse Cheshire- As mentioned at 1 hour 47 minutes https://www.woodlandtrust.org.uk/visiting-woods/woods/wheeldon-copse/ National Vegetation Classification (NVC) with John Rodwell - As mentioned at 1 hour 49 minutes https://englandscommunityforests.org.uk/ecf-news/national-vegetation-classification-with-john-rodwell

Footnotes: Paul Farley; As mentioned at 1 hour 19 minutes https://www.leadinglanguageandliteraturepodcast.com/episodes/paul-farley-poet-and-professor-of-creative-writing-lancaster Soil Inversion case study; https://cieem.net/wp-content/uploads/2019/03/1.-Philip-Putwain.pdf Tony Bradshaw- Restoration ecologist- As mentioned at 1 hour 42 minutes https://www.theguardian.com/science/2008/sep/11/evolution Halewood Triangle- As mentioned at 1 hour 42 minutes https://www.woodlandtrust.org.uk/visiting-woods/woods/halewood-park-triangle/ Gunnersbury Triangle- As mentioned at 1 hour 42 minutes https://www.woodlandtrust.org.uk/visiting-woods/woods/halewood-park-triangle/ Wheeldon Copse Cheshire- As mentioned at 1 hour 47 minutes https://www.woodlandtrust.org.uk/visiting-woods/woods/wheeldon-copse/ National Vegetation Classification (NVC) with John Rodwell - As mentioned at 1 hour 49 minutes https://englandscommunityforests.org.uk/ecf-news/national-vegetation-classification-with-john-rodwell Episode segments Edit audio

Useful resource; The Ecological Restoration and Habitat Creation Special Interest Group: Practical Restoration and Creation: Lowland and Upland Grasslands https://cieem.net/resource/cieem-erhc-sig-east-midlands-section-committee-2019-conference-dr-phil-sterling/ Jane Jacobs- The Death and Life of Great American Cities - As mentioned at 11 minutes https://www.amazon.co.uk/Death-Great-American-Cities-Vintage/dp/067974195X National Vegetation Classification:As mentioned at 13 minutes https://hub.jncc.gov.uk/assets/a407ebfc-2859-49cf-9710-1bde9c8e28c7 St Vincent School- As mentioned at 21:30 minutes https://www.stvin.com

In this episode we speak with Dr. Richard Scott about his work studying Uto-Aztecan premolars! Article title: Multiple occurrences of the rare Uto-Aztecan premolar variant in Hungary point to ancient ties between populations of western Eurasia and the Americas

Fertility & Sterility brings you some great interviews from ASRM 2022 in Anaheim, CA! In Part 1, we discuss science with leaders in the field and prefesenters from the conference. Topics this month include career-focused women and family planning (Jen Bakkenson) (3:20), live imaging of embryo development (Nicholas Plachta) (8:02), predicting outcomes using AMH in fertilty preservation (Cassandra Roeca) (19:15), IVF stimulation outcomes by race and ethnicity (Iris Lee) (21:09), a chat with Dr. Beth Rakowsky (30:53), assessing expansion of fertility preservation coverage (Allison Komorowski) (35:47), a discussion on uterine NK cells in reproduction (Jessica Kanter) (39:56), the potential of mitochondrial enhacement (Richard Scott) (44:15), updates in recurrent implantation failure (Paul Pirtea, Dominique De Ziegler) (49:43) and a discussion about male infertility (Luis Hoyos, Thomas Masterson) (1:00:18). View Fertility and Sterility at https://www.fertstert.org/

Episode 64: What Happened to Richard Scott Embry?https://www.14news.com/story/13715286/miller-pleads-not-guilty-in-owensboro-murder-case/https://www.14news.com/story/13497261/person-of-interest-identified-in-owensboro-murder/https://www.14news.com/story/13506397/opd-miller-has-lengthy-criminal-record/Richard Scott Embry's song “Doin Time” https://www.youtube.com/watch?v=VzxP66XI6Ok To Become a Patreon Supporter: https://www.patreon.com/operationevilpodcastBuzzsprout Link: https://www.buzzsprout.com/?referrer_id=1785489Support the show

A special today recorded live at Wayne Holloway-Smith's house. Three wonderful poets share new work many of which have never been heard before! Presenting the brilliant Will Harris, known for his brilliant book Rendang. Also, the great Richard Scott who's published with Faber his book Soho was a game changer. And finally, Lucy Mercer whose debut book Emblem is something to behold. All of these great poets here to entertain you for 15 brilliant minutes. Will Harris - https://willjharris.com/poems Richard Scott - http://richardscott.info/poetry.html Lucy Mercer - https://lucy-mercer.com/writing

It's Wednesday, September 28th, A.D. 2022. This is The Worldview in 5 Minutes heard at www.TheWorldview.com.  I'm Adam McManus. (Adam@TheWorldview.com) By Jonathan Clark Hong Kong Bishop on trial for pro-democracy protests A 90-year-old former bishop of Hong Kong went on trial Monday for his support of pro-democracy protests in 2019. Cardinal Joseph Zen is known for speaking out against China's Communist Party which has asserted control over Hong Kong. Police originally arrested the bishop in May. Shortly after China introduced its National Security Law for Hong Kong in 2020, Cardinal Zen said he was ready to face trial and imprisonment.  Cubans voted for faux homosexual marriage & homosexual adoption The whirlwind of sexually perverted lifestyles has been let loose on Cuba. On Sunday, Cubans voted in favor of a new family code that legalizes faux homosexual marriage as well as adoption for homosexual couples. Sixty-six percent of voters supported the referendum while 33% opposed it. Meanwhile, a different storm made landfall in Cuba this week. Hurricane Ian slammed into the island on Tuesday. The Category 3 storm caused mass evacuations, power outages, and flooding. Britain's Nat'l Health Service reluctantly allows doctor to pray On Monday, England's National Health Service agreed to a settlement with a Christian doctor facing disciplinary measures for offering to pray with his patients.  The NHS investigated Dr. Richard Scott for years based on hearsay complaints. The regulatory body even threatened to remove him from the NHS Practitioners List unless he took a nearly $2,000 “professional boundaries” course at his own expense. The recent settlement says Dr. Scott is allowed to offer to pray with his patients.   Dr. Scott told Christian Concern in a video that the next generation of doctors in England live in fear of expressing their faith. SCOTT: “We now have generation of young doctors who are so scared to open their mouth for Jesus in case the National Secular Society, the General Medical Council, NHS England or anybody else, the British Humanist Association, complains. And would rather they didn't get a complaint because it can be very stressful.” Southern Baptist denomination kicks out pro-homosexual church The Executive Committee of the Southern Baptist Convention decided to disfellowship a congregation last week over its open affirmation of homosexuality. Texas pastor Jared Wellman, who serves as the Southern Baptist Executive Committee chairman, told Baptist Press the congregation was “outside the bounds of fellowship with Southern Baptists.”  College Park Baptist Church in Greensboro, North Carolina was founded in 1906. Its website states it is a “Welcoming, LGBTQIA Affirming Baptist Church.”  That's quite an alphabet soup there. James 4:4 says, “Adulterers and adulteresses! Do you not know that friendship with the world is enmity with God? Whoever therefore wants to be a friend of the world makes himself an enemy of God.” Two anti-abortion laws in Arizona Two anti-abortion laws took effect in Arizona last week. On Friday, a county judge reinstated an 1864 law that bans nearly all abortions. The law has not been in effect since the Supreme Court's Roe v. Wade decision. However, the judge reinstated the law in light of the court's reversal of Roe this year.  A second Arizona law also took effect Saturday, banning abortions after 15 weeks of pregnancy. Planned Parenthood Arizona is suspending abortions in response to the laws. Pro-life canvasser shot in back On September 20th, a short, 83-year-old pro-life Michigan woman was going door to door in Odessa Township, volunteering her time to urge voters to vote against Proposal 3, a pro-abortion constitutional amendment on the November ballot, reports Channel 8 News. Anna Visser, director of Communication and Education for Michigan Right to Life, summarized what happened when she came to the home of Richard and Sharon Harvey. VISSER: “From her account, the lady, [Sharon Harvey], that answered the door, was upset with her, started screaming at her. And then, as she was walking away, a man, [Richard Harvey], from the house whom she wasn't originally talking to, he came out, and shot her in the back as she was walking away.” The volunteer, who has chosen to remain anonymous, drove herself to the Lake Odessa Police Department and was then treated and released from the hospital. Richard Harvey claims he shot her by accident. The 83-year-old pro-lifer is a long-time volunteer and has had no complaints about how she has discussed the abortion issue at the doorstep of people's homes. According to a Michigan Right to Life press release, the out-of-control rhetoric of President Joe Biden and Democratic Michigan Governor Gretchen Whitmer must end with the shooting of a pro-life volunteer. Visser said, “She is recovering well and is in good spirits.” Americans confused about whether we are a Christian nation The University of Maryland's Critical Issues Poll found 70% of Americans think the U.S. Constitution would not allow the U.S. government to declare the United States a Christian nation. Sixty-two percent of Americans also oppose the United States officially declaring itself to be a Christian nation.  John Jay, the  First Chief Justice of the U.S. Supreme Court, wrote, “Providence has given to our people the choice of their ruler, and it is the duty, as well as the privilege and interest of our Christian nation to select and prefer Christians for their rulers.” Not surprisingly, a majority of Republicans (at 61%) are in favor of the U.S. declaring itself a Christian nation.  Psalm 9:17, 20 says, “The wicked shall be turned into hell, and all the nations that forget God. … Put them in fear, O LORD, that the nations may know themselves to be but men.” Tennessee Governor's acknowledgement of God's sovereignty And finally, Tennessee's Republican Governor Bill Lee  signed a proclamation declaring Friday, September 30 a day of prayer, humility, and fasting. The proclamation declared, “We acknowledge God's sovereignty and the need for God's grace over our state and our nation. …. We seek forgiveness for our many transgressions so that our hearts and our minds may be renewed.  … Scripture tells us that the beginning of wisdom is the fear of the Lord, and the Lord gives wisdom freely to those who ask for it. … The people of Tennessee acknowledge our rich blessings, our deep transgressions, the complex challenges ahead, and the need to pause, to humble ourselves and to seek God's guidance for the days ahead.” Close And that's The Worldview in 5 Minutes on this Wednesday, September 28th, in the year of our Lord 2022. Subscribe by iTunes or email to our unique Christian newscast at www.TheWorldview.com. Or get the Generations app through Google Play or The App Store. I'm Adam McManus (Adam@TheWorldview.com). Seize the day for Jesus Christ.

In this week's episode Dr Scott shares his journey to becoming a consultant clinical geneticist and the Chief Medical Officer (CMO) at Genomics England. We delve into his passion for clinical genetics, the misconceptions and the barriers medical professionals and general public have understanding the true nature of genomics.   Richard shares his desire to harness the power of genomic technologies for the benefit of all patients in mainstream healthcare. We spend time understanding the path he took to becoming a consultant and CMO, in such a niche medical specialty. We discuss the role of Genomics England and how they are helping improve the diagnosis and treatment of patients in the NHS through their scientific research. Richard explains how pivotal their work is for the future of healthcare and why it is so important communities from across the UK become actively informed and involved.  Learn more about Richard: Dr Richard Scott is Chief Medical Officer at Genomics England, Consultant and Honorary Associate Professor in Clinical Genetics at Great Ormond Street Hospital for Children and the UCL Institute of Child Health where his practice focuses on diagnosing children with rare multisystem disorders.  Richard trained in medicine at Cambridge University and University College London. He specialised in Paediatrics and subsequently Clinical Genetics in London and completed his PhD on childhood cancer syndromes at the Institute of Cancer Research. Twitter: @Rich_Genomics https://www.genomicsengland.co.uk/ ------------------------------------- Episode sponsored by MySuture  MySuture™  is an all in one suture practice kit and digital learning platform with direct access to Surgeon advice & training. With this all in one suture practice kit and the MySkills™ digital learning platform, you can learn to suture anytime, anywhere.  The all in one suture simulation kit includes high quality silicone made of advanced nontoxic materials, with height simulation skin, 14 pre-cut wounds, 3 layers including skin, subcutaneous fat and muscle with a mesh reinforcement to provide suture retention, mimic natural anatomy and create a true to life texture.  Buy your suture kit now at: mysuture.com  MySuture Socials: Twitter | Instagram ------------------------------------- Check out our latest platform Peerr Where healthcare professionals learn from the best educators - your peers! ✍️ Make your own quizzes for revision - An invaluable learning tool

Best friend. Head coach. Husband. Red Roses lock Abbie Ward and Bristol Bears Women head coach Dave Ward have an unique sporting and personal relationship, having to combine their marriage with a working life at the Allianz Premier 15s side. On this England Rugby Podcast: O2 Inside Line, Abbie also talks about the difficult discussion she had with her dad about wanting to become a rugby player, her business plan to go to boarding school and life growing up in Cumbria.This pod will also hear contributions from her husband Dave, Abbie's father Richard Scott as well as team mates Marlie Packer and Shaunagh Brown, along with England forwards coach Louis Deacon.FOLLOW:· England Rugby Facebook· England Rugby Instagram· England Rugby Twitter· England Rugby TikTok· O2 Sports Instagram· O2 Sports Twitter SUBSCRIBE:· Subscribe to the pod here. BUY:· Get the latest kits, training and leisure wear from England Rugby StoreAUDIO CREDIT· With thanks to BT Sport for permission to use their Premiership commentary See acast.com/privacy for privacy and opt-out information.

Richard Scott has been rocking the world of CG for more than 30 years. He began his career in graphic design, moved into 3D for broadcast and commercials, and then got involved with cutscenes for the games industry. He founded Axis Studios in 2000, and it's steadily grown to a team of 400 people working on VFX and animation for movies, TV, games, and theme parks. Richard discusses his history in CG, from Quantel paintboxes and Lightwave to modern workflows. He also talks about his involvement in the Scottish animation scene, Axis' “The Tall Grass” segment of Love, Death and Robots, and its upcoming animated feature film — which employed an animation supervisor based in Australia. April is Autism Acceptance Month, and Chaos is highlighting some of the upcoming graduates of Exceptional Minds. This week, we have Mina McCauley, who will be graduating with an emphasis in VFX. You can check out her work on Creatively.To learn more about Exceptional Minds, visit exceptional-minds.org or find them on social.

“Let's talk about patients. That's where we have to always begin. This is about patients. I was tremendously impressed with how much the patient advocacy groups had accomplished, that helped us make judgments that are really complex and very dangerous judgments. All that played into the success. Then, of course, it was very rapidly approved around the world.” In this week's episode of The G Word, Dr Richard Scott, our Chief Medical Officer, is joined by Dr Stanley Crooke, M.D., Ph.D., the founder, chairman of the board and Chief Executive Officer of n-Lorem. In this episode, Dr Scott and Dr Crooke discuss the foundation of n-Lorem, the importance of patient advocacy groups and the spinal muscular atrophy treatment Spinraza. They also discussed the value of whole genome sequencing in newborn screening.

Andrew is joined with Dr. Stephen Guy-Bray who queers the Shakespeare canon, and with his scholarly expertise, explains what it means to provide a queer and homoerotic approach to Shakespeare's oeuvre. Get ready to learn why the queerness of a text is in the hands of its reader. To see more of Dr. Stephen Guy-Bray's work head here: https://english.ubc.ca/profile/stephen-guy-bray/ Follow Dr. Stephen Guy-Bray on Instagram, @stephen.guybray, and Twitter, @SGUYBRAY. You can find his book Shakespeare and Queer Representation (2020) on Routledge's site: https://www.routledge.com/Shakespeare-and-Queer-Representation/Guy-Bray/p/book/9781138389618 Become a Patreon subscriber and you'll get access to the video version of this interview: https://www.patreon.com/ivorytowerboilerroom To see more of Richie Hofmann and Richard Scott's poetry, make sure to follow them on Twitter, @RichieHof and @iamrichardscott. Follow Ivory Tower Boiler Room on Facebook, @ivorytowerboilerroom, Instagram, @ivorytowerboilerroom, TikTok, @ivorytowerboilerroom, and Twitter, @IvoryBoilerRoom! Email us at ivorytowerboilerroom@gmail.com. We love hearing from you about the podcast and are always interested in interview suggestions. Many thanks to the Ivory Tower Boiler Room podcast team: Andrew Rimby, Executive Director; Mary DiPipi, Chief Contributor; Ceren Usta, Marketing Director Podcast Interns: Nicole Arguello and Kimberly Dallas Educational Fair Use: Thanks to Ghostlight Records for "Welcome to the Renaissance" (from Something Rotten!). --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/ivorytowerboilerroom/support

Some criminals don't use crowbars to rob you, they use love instead. For the women who met and fell in love with Richard Scott Smith, they thought they had finally found the man they wanted to spend the rest of their life with but what started as romance ended in a nightmare of deceit and debt. Featuring interviews with Sandi and Carla Campbell from the Showtime docu-series "Love Fraud" If you like the show, please rate and review and be sure to follow the show on social media: Instagram: @thestrangeryouknowpodcast Twitter: @tsykpod Sources: ‘It could happen to you': inside the shocking true story of the docuseries Love Fraud. By: Adrian Horton. https://www.theguardian.com/tv-and-radio/2020/aug/25/love-fraud-showtime-documentary-con-man Con Man Richard Scott Smith. http://scottthecrooksmith.weebly.com Richard Scott Smith of Love Fraud Is Still Conning Women. By: Elena Nicolaou. https://www.oprahdaily.com/entertainment/a33915040/richard-scott-smith-love-fraud-now/ The True Story Behind Love Fraud and Richard Scott Smith. By: Adam Rathe. https://www.townandcountrymag.com/leisure/arts-and-culture/a33821604/love-fraud-richard-scott-smith-true-story/ Love Fraud. Showtime. https://www.sho.com/love-fraud How ‘Love Fraud' lothatio Scott Smith ‘scammed' women out of $1 million. By: Michael Kaplan. https://nypost.com/2020/08/29/how-love-fraud-scott-smith-scammed-women-out-of-1-million/ Love Fraud May Just Solve The Mystery of Whatever Happened to Richard Scott Smith. By: Sarah Midkiff. https://www.refinery29.com/en-us/2020/08/9960382/where-is-richard-scott-smith-now-love-fraud Emotional Piano Background Music. Migfus20. https://freesound.org/people/Migfus20/sounds/560448/ --- Send in a voice message: https://anchor.fm/thestrangeryouknowpodcast/message

Welcome to the CavasShips Podcast with Christopher P. Cavas and Chris Servello…a weekly podcast looking at naval and maritime events and issues of the day – in the US, across the seas and around the world. This week…a discussion with Richard Scott, one of Britain's leading naval correspondents about the Royal Navy's new Queen Elizabeth-class carriers, the first of which is now leading an international task group on a historic deployment to the Indo-Pacific region. In this Week's Squawk Chris Cavas talks about the goods and bads of locking in ship designs. Please send us feedback by DM'ing @CavsShips or @CSSProvision or you can email chriscavas@gmail.com or cservello@defaeroreport.com .

At the end of all of our interviews, Steve and I always ask our guests two questions: what is something they think that needs to live and what is something that needs to die in the mining industry? We thought it would be interesting to put together some of these responses we have received to those questions over the years. So on this episode of Ideas That Must, we are joined by, in order, Mark Bennett, Attila Pentek, Richard Scott, Holly Bridgwater, Mark Bennett (again), Marcus Lake, Michelle Carey, Holly Bridgwater (again), Justin Strharsky and Samantha Copeland. Let's find out what they had to say.

Billy Big Time. Showtime. Action

In this episode, I sit down with Drs G. Richard Scott and Marin Pilloud to talk about their article and resulting application: "rASUDAS: A New Web-Based Application for Estimating Ancestry from Tooth Morphology", which was co-authored and developed with David Navega, João d'Oliveira Coelho, Eugénia Cunha, and Joel D. Irish. If you would like to use the rASUDAS application, you can access it at https://www.osteomics.com. We would love to hear from you! If you have any suggestions for any special episodes or would like to get involved and interview researchers in the field, reach out to us @JForensicAnth

Why do some people have a severe response to COVID-19, and others seem to have no symptoms at all? Is the answer in our genes? This week we talk to Chris Wigley, the CEO of Genomics England and Interim SRO for Data-NHSX, and Dr Richard Scott, the clinical lead for rare disease at Genomics England and consultant clinical geneticist at Great Ormond Street. Genomics England has led the UK into a new world of medicine with genetic sequencing, and it's only just starting. Today, we're focusing on the recently announced large scale human genome sequencing project launched by Genomics England in regards to COVID-19. From understanding individual response and drug development, listen to what Genomics England are hoping to understand about COVID-19. If you would like to volunteer for Genomics England's study on COVID19, sign up here: https://www.genomicsengland.co.uk/covid-19/

A quick glimpse into Switchboard's log books from the late 70s might make you think that every caller wanted to know about sex. Tash and Adam hear from former volunteers such as Femi Otitoju on advising callers about how to do it, where to cruise, and importing sex toys. Contemporary poems from Michelle Mangal, Annie Hayter and Richard Scott put sex lives into modern words.Content warning: sexual content.The Log Books — stories from Britain's LGBT+ history and conversations about being queer today. Produced by Shivani Dave, Adam Smith and Tash Walker, in partnership with Switchboard - the LGBT+ helpline.Poems:Mooncup by Michelle MangalPublic Toilets in Regent's Park by Richard Scott, reproduced with the kind permission of Faber and FaberGod-birth by Annie HayterFor more information about the items in this episode, take a look at:Mens R Us info for men having sex with menUnexpected Fluids podcastBeating about the bush sexual health guide for lesbiansLesbian Sex 101 Back Pocket Guide Trans Men Juno Roche on her book Queer SexRisk Aware Consensual Kink Music by Tom Foskett-BarnesArtwork by Natalie Dotohttps://www.thelogbooks.orgSupport this show http://supporter.acast.com/thelogbooks. See acast.com/privacy for privacy and opt-out information.

As the National Leagues kicked off at the weekend, the NL Full Time team travelled far and wide to capture reaction from all three divisions! Rob caught up with AFC Fylde Manager Dave Challinor after their narrow opening day victory, whilst Luke spoke with Harrogate Town boss Simon Weaver and Solihull Moors Callum Howe after their four-goal thriller. Meanwhile Chris witnessed Stockport County's first game back in the top tier of Non-League, only for Alan Devonshire's Maidenhead United to take on the role of chief 'party-poopers'. Richard Scott got audio with Chorley's Vermiglio & Bromley's Neil Smith after they shared the spoils. Thom wraps up the National League South action and chats to Billericay Town's Jake Robinson following his late, late winner and also with Dorking's Marc White after their first ever Step 2 victory!Finally Dickie caught up with Kettering Town boss Nicky Eaden after their opening day win against AFC Telford and looks ahead to the midweek fixtures.    Hosted on Acast. See acast.com/privacy for more information. Learn more about your ad choices. Visit podcastchoices.com/adchoices

This week Luke is joined by the editor of the Non-League Paper, Alex Narey, as they look at how the National League season is shaping up so far.  There is a look at the FA Cup Third Qualifying round, Richard Scott catches up with Bradford Park Avenue Manager, Mark Bower and the Step 3 focus this week is on Workington AFC. Hosted on Acast. See acast.com/privacy for more information. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Who:  Richard Scott, Mindset Coach and Hypnotherapist What We Talked About:  How to release phobias.  Phobias are irrational fears.  Common phobias include insects, heights, water, and dogs, and sometimes even more “close to business” phobias like a fear of numbers or a fear of public speaking.  In this interview, Richard explained that it is possible to get over these phobias in as little as one session and he revealed an easy-do-it-yourself solution too.   Why I Like Richard:  He's a giver.  He loves helping people and he has a lot of tools in his tool belt.  Not only has he had success with phobias, he's also helped many people lose weight and deal with stress, all by untapping the power of their minds. Great Line:  Break your phobia down logically rather than emotionally. Where to Learn More:  http://www.mynd.works     http://www.themindawareshow.com